Loading…
Underlying
Underlying Price
$8.28
Type
Put
Strike
8
Expiration
Nov 20, 2026
DTE
31d
Moneyness
OTM
Intrinsic
$0.00
IBRX 8 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.50 | +11.11% | 3 | 113 |
| Oct 30, 2026 | 10d | $0.25 | +92.31% | 2 | 150 |
| Nov 6, 2026 | 17d | $0.33 | +13.79% | 1 | 69 |
| Nov 13, 2026 | 24d | $0.75 | +114.29% | 1 | 66 |
| Nov 20, 2026 | 31d | $0.55 | +30.95% | 264 | 2,195 |
| Nov 27, 2026 | 38d | $0.55 | +30.95% | 2 | 10 |
| Dec 18, 2026 | 59d | $0.70 | +0.00% | 1 | 1,197 |
| Mar 19, 2027 | 150d | $1.36 | -15.00% | 292 | 738 |
| Apr 16, 2027 | 178d | $1.59 | +0.00% | 1 | 1 |
| May 21, 2027 | 213d | $1.70 | -5.56% | 40 | 45 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 P | $0.10 | -50.00% | 3 | 2 | OTM |
| 3 P | — | — | 0 | 0 | OTM |
| 4 P | $0.03 | -40.00% | 1 | 6 | OTM |
| 5 P | $0.10 | +0.00% | 1 | 256 | OTM |
| 6 P | $0.10 | -23.08% | 250 | 3,143 | OTM |
| 7 P | $0.25 | +66.67% | 1,067 | 4,059 | OTM |
| 8 P | $0.55 | +30.95% | 264 | 2,195 | OTM |
| 9 P | $0.90 | +21.62% | 65 | 1,572 | ITM |
| 10 P | $1.48 | +28.70% | 99 | 741 | ITM |
| 11 P | $2.20 | +41.03% | 7 | 394 | ITM |
| 12 P | $2.20 | -26.67% | 20 | 74 | ITM |
| 13 P | $3.60 | +16.88% | 2 | 3 | ITM |
| 14 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.